UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.866-866

2015

Volltextzugriff (PDF)

AB0805 Long-Term Impact of Apremilast on Physical Function in Patients with Psoriatic Arthritis Using the HAQ-DI Assessment

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1168-1168

2015

Volltextzugriff (PDF)

Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis

Value in health, 2014-11, Vol.17 (7), p.A376-A376

2014

Volltextzugriff (PDF)

Impact of Apremilast on Physical Function over 52 weeks in Patients with Active Psoriatic Arthritis

Value in health, 2014-11, Vol.17 (7), p.A372-A372

2014

Volltextzugriff (PDF)

Impact Of Apremilast On Physical Function In Patients With Psoriatic Arthritis

Value in health, 2014-05, Vol.17 (3), p.A41-A41

2014

Volltextzugriff (PDF)

Economic Evaluation Of Sequencing Strategies In The Treatment Of Psoriatic Arthritis In The United States

Value in health, 2014-05, Vol.17 (3), p.A46-A46

2014

Volltextzugriff (PDF)

Characteristics of adult medicaid beneficiaries with schizophrenia treated with paliperidone palmitate and predictors of treatment continuity

Value in health, 2013-05, Vol.16 (3), p.A69-A69

2013

Volltextzugriff (PDF)

Factors associated with performance on the medicaid hedis measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia

Value in health, 2014-05, Vol.17 (3), p.A218-A219

2014

Volltextzugriff (PDF)

An assessment of clinical outcomes among adults with schizophrenia and/or schizoaffective disorder following a change in antipsychotic therapy

Value in health, 2013-05, Vol.16 (3), p.A56-A56

2013

Volltextzugriff (PDF)

PMS59 - Healthcare Costs In Psoriatic Arthritis Patients Newly Initiated on Apremilast or Biologic Therapies

Value in health, 2015-11, Vol.18 (7), p.A644-A644

2015

Volltextzugriff (PDF)

Healthcare Costs In Psoriatic Arthritis Patients Newly Initiated on Apremilast or Biologic Therapies

Value in health, 2015-11, Vol.18 (7), p.A644-A644

2015

Volltextzugriff (PDF)

PCN72 - Assessing Patient-Reported Outcomes and Work Productivity Along the Multiple Myeloma (MM) Patient Journey

Value in health, 2018-09, Vol.21, p.S18-S18

2018

Volltextzugriff (PDF)

Assessing Patient-Reported Outcomes and Work Productivity Along the Multiple Myeloma (MM) Patient Journey

Value in health, 2018-09, Vol.21, p.S18

2018

Volltextzugriff (PDF)

Health Care Costs in Psoriasis Patients Newly Initiated on Apremilast or Biologic Therapies

Value in health, 2016-05, Vol.19 (3), p.A128-A128

2016

Volltextzugriff (PDF)

PSS34 - Health Care Costs in Psoriasis Patients Newly Initiated on Apremilast or Biologic Therapies

Value in health, 2016-05, Vol.19 (3), p.A128-A128

2016

Volltextzugriff (PDF)

PCN118 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Value in health, 2020-05, Vol.23, p.S43-S43

2020

Volltextzugriff (PDF)

PCN104 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

Value in health, 2020-05, Vol.23, p.S41-S41

2020

Volltextzugriff (PDF)

OBSERVATIONAL STUDY COMPARING TREATMENT PERSISTENCE IN BIOLOGICNAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR ETANERCEPT

Value in health, 2017-05, Vol.20 (5), p.A159

2017

Volltextzugriff (PDF)

PMS19 - Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis

Value in health, 2014-11, Vol.17 (7), p.A376-A376

2014

Volltextzugriff (PDF)

PSS21 - Real-World Cost Per Persisting Patient: Comparing Psoriasis Patients Initiated on Apremilast or Biologic Therapies

Value in health, 2016-05, Vol.19 (3), p.A125-A126

2016

Volltextzugriff (PDF)

Comparison of Persistence between Adults with Psoriasis Initiating Apremilast or Biologics

Value in health, 2016-05, Vol.19 (3), p.A126-A126

2016

Volltextzugriff (PDF)

Real-World Cost Per Persisting Patient: Comparing Psoriasis Patients Initiated on Apremilast or Biologic Therapies

Value in health, 2016-05, Vol.19 (3), p.A125-A126

2016

Volltextzugriff (PDF)

PSS22 - Comparison of Persistence between Adults with Psoriasis Initiating Apremilast or Biologics

Value in health, 2016-05, Vol.19 (3), p.A126-A126

2016

Volltextzugriff (PDF)

PSY55 - Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in health, 2018-05, Vol.21, p.S254-S254

2018

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Value in health, 2018-05, Vol.21, p.S254

2018

Volltextzugriff (PDF)

1 – 25 von 254

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(236)
Mit Volltextzugriff
(229)

Publikationsform

Sprache

Englisch
(253)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(142)
Life Sciences & Biomedicine
(116)
Humans
(82)
Biological And Medical Sciences
(62)
Male
(48)
Female
(47)
Animals
(38)
Fundamental And Applied Biological Sciences. Psychology
(35)
Medical Sciences
(30)
Adult
(28)
Microbiology
(23)
Physical Sciences
(21)
Adolescent
(20)
General & Internal Medicine
(19)
Internal Medicine
(19)
Middle Aged
(18)
Technology
(17)
Medicine, General & Internal
(15)
Immunology
(14)
Mice
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

SAT0568 Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies

AB0805 Long-Term Impact of Apremilast on Physical Function in Patients with Psoriatic Arthritis Using the HAQ-DI Assessment

Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis

Impact of Apremilast on Physical Function over 52 weeks in Patients with Active Psoriatic Arthritis

Impact Of Apremilast On Physical Function In Patients With Psoriatic Arthritis

Economic Evaluation Of Sequencing Strategies In The Treatment Of Psoriatic Arthritis In The United States

Characteristics of adult medicaid beneficiaries with schizophrenia treated with paliperidone palmitate and predictors of treatment continuity

Factors associated with performance on the medicaid hedis measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia

An assessment of clinical outcomes among adults with schizophrenia and/or schizoaffective disorder following a change in antipsychotic therapy

PMS59 - Healthcare Costs In Psoriatic Arthritis Patients Newly Initiated on Apremilast or Biologic Therapies

Healthcare Costs In Psoriatic Arthritis Patients Newly Initiated on Apremilast or Biologic Therapies

PCN72 - Assessing Patient-Reported Outcomes and Work Productivity Along the Multiple Myeloma (MM) Patient Journey

Assessing Patient-Reported Outcomes and Work Productivity Along the Multiple Myeloma (MM) Patient Journey

Health Care Costs in Psoriasis Patients Newly Initiated on Apremilast or Biologic Therapies

PSS34 - Health Care Costs in Psoriasis Patients Newly Initiated on Apremilast or Biologic Therapies

PCN118 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

PCN104 TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)TREATMENT PATTERNS AND HEALTH CARE COSTS IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) OR MARGINAL ZONE LYMPHOMA (MZL)

OBSERVATIONAL STUDY COMPARING TREATMENT PERSISTENCE IN BIOLOGICNAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR ETANERCEPT

PMS19 - Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis

PSS21 - Real-World Cost Per Persisting Patient: Comparing Psoriasis Patients Initiated on Apremilast or Biologic Therapies

Comparison of Persistence between Adults with Psoriasis Initiating Apremilast or Biologics

Real-World Cost Per Persisting Patient: Comparing Psoriasis Patients Initiated on Apremilast or Biologic Therapies

PSS22 - Comparison of Persistence between Adults with Psoriasis Initiating Apremilast or Biologics

PSY55 - Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, And Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)

Suchergebnisse filtern